Literature DB >> 28554832

Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.

B Xu1, R Ghossein2.   

Abstract

The vast majority of low grade follicular cell derived thyroid carcinomas follows an indolent clinical course and is associated with very low mortality. Risk stratification using multiple clinical and pathologic characteristics has become the standard of care to guide appropriate management and avoid overtreatment. Over the past few decades, the field of thyroid pathology has witnessed several major changes that significantly impacted upon patients' care. These are: 1) The reclassification of non-invasive encapsulated follicular variant of papillary thyroid carcinoma as noninvasive follicular thyroid neoplasm with papillary-like nuclear features; 2) the diagnosis of Hurthle cell carcinoma based on the presence of capsular and vascular invasion; 3) a detailed definition of poorly differentiated thyroid carcinoma, taking into consideration mitosis and necrosis; and 4) the emphasis on a detailed pathologic analysis such as the extent of vascular invasion and extrathyroidal extension. This review describes these histological concepts and details the history, rationale, and clinical impacts of such changes. These shifts in the classification and characterization of thyroid carcinoma provided a platform supporting therapy de-escalation. In addition several lessons were learned from these changes especially from the misclassification of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma. We hope that the lessons learned will help better classify tumors in the future whether arising in the thyroid or other organs.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Extensive vascular invasion; Extrathyroidal extension; Hurthle cell carcinoma; Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); Poorly differentiated thyroid carcinoma

Mesh:

Year:  2017        PMID: 28554832      PMCID: PMC5694380          DOI: 10.1016/j.ejso.2017.05.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  67 in total

1.  Why there is the tendency to "overdiagnose" the follicular variant of papillary thyroid carcinoma.

Authors:  Andrew A Renshaw; Edwin W Gould
Journal:  Am J Clin Pathol       Date:  2002-01       Impact factor: 2.493

2.  Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma.

Authors:  John K C Chan
Journal:  Am J Clin Pathol       Date:  2002-01       Impact factor: 2.493

3.  Risk stratification of follicular variant of papillary thyroid carcinoma.

Authors:  Marina Vivero; Stefan Kraft; Justine A Barletta
Journal:  Thyroid       Date:  2013-03       Impact factor: 6.568

4.  Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.

Authors:  Jeffrey Liu; Bhuvanesh Singh; Giovanni Tallini; Diane L Carlson; Nora Katabi; Ashok Shaha; R Michael Tuttle; Ronald A Ghossein
Journal:  Cancer       Date:  2006-09-15       Impact factor: 6.860

5.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

6.  Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.

Authors:  Jamal Zidan; Drumea Karen; Moshe Stein; Edward Rosenblatt; Walid Basher; Abraham Kuten
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

7.  Follicular variant of papillary thyroid carcinoma. A clinicopathologic study.

Authors:  E T Tielens; S I Sherman; R H Hruban; P W Ladenson
Journal:  Cancer       Date:  1994-01-15       Impact factor: 6.860

8.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors:  Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

9.  Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma.

Authors:  Brooke E Howitt; Yonghui Jia; Lynette M Sholl; Justine A Barletta
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

10.  Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.

Authors:  Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

View more
  10 in total

1.  Cause-specific mortality after diagnosis of thyroid cancer: a large population-based study.

Authors:  Binbin Du; Fang Wang; Leiming Wu; Zheng Wang; Dianhong Zhang; Zhen Huang; Lu Gao; Yapeng Li; Cui Liang; Pengcheng Li; Rui Yao
Journal:  Endocrine       Date:  2020-08-08       Impact factor: 3.633

Review 2.  Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine.

Authors:  Antonio Ieni; Roberto Vita; Cristina Pizzimenti; Salvatore Benvenga; Giovanni Tuccari
Journal:  J Pers Med       Date:  2021-04-23

Review 3.  Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).

Authors:  Chiara Diquigiovanni; Elena Bonora
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

4.  Alternation between toxic and proliferative effects of Roundup® on human thyroid cells at different concentrations.

Authors:  Izabela Fernanda Dal' Bó; Elisângela Souza Teixeira; Larissa Teodoro Rabi; Karina Colombera Peres; Matheus Nascimento; Maria Izabel Chiamolera; Valdemar Máximo; Natássia Elena Bufalo; Laura Sterian Ward
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-29       Impact factor: 6.055

5.  Seemingly Harmless Differentiated Thyroid Carcinoma Presenting as Bone Metastasis.

Authors:  D Magalhães; C Costa; I Furtado; M J Matos; A P Santos; H Duarte; M Afonso; J Lobo; I Torres
Journal:  Case Rep Endocrinol       Date:  2018-06-03

6.  SDC4 Gene Silencing Favors Human Papillary Thyroid Carcinoma Cell Apoptosis and Inhibits Epithelial Mesenchymal Transition via Wnt/β-Catenin Pathway.

Authors:  Liang-Liang Chen; Ge-Xin Gao; Fei-Xia Shen; Xiong Chen; Xiao-Hua Gong; Wen-Jun Wu
Journal:  Mol Cells       Date:  2018-08-31       Impact factor: 5.034

Review 7.  Nutritional and Environmental Factors in Thyroid Carcinogenesis.

Authors:  Immacolata Cristina Nettore; Annamaria Colao; Paolo Emidio Macchia
Journal:  Int J Environ Res Public Health       Date:  2018-08-13       Impact factor: 3.390

8.  A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma.

Authors:  Xian Wang; Shan Huang; Xiaocan Li; Dongrui Jiang; Hongzhen Yu; Qiang Wu; Chaobing Gao; Zhengsheng Wu
Journal:  PLoS One       Date:  2018-07-13       Impact factor: 3.240

9.  Identification of key candidate genes and pathways in follicular variant papillary thyroid carcinoma by integrated bioinformatical analysis.

Authors:  Lanyu Jing; Fada Xia; Xin Du; Bo Jiang; Yong Chen; Xinying Li
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

10.  Synergistic effects of histologic subtype, T-stage, and M-stage in the prognosis of differentiated thyroid cancer: a retrospective observational study.

Authors:  Ling Zhou; Shipei Wang; Sichao Chen; Yihui Huang; Di Hu; Wei Wei; Chao Zhang; Min Wang; Wei Zhou; Wen Zeng; Zeming Liu; Liang Guo
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.